Background. Ceftolozane/tazobactam (C/T) is a relatively new antipseudomonal cephalosporin combined with a β-lactamase inhibitor approved by the FDA in 2014. The study goal was to evaluate its in vitro activity vs. comparator agents against a pre-selected panel of Pseudomonas isolates obtained from pediatric patients with cystic fibrosis.
Methods. Clinical Pseudomonas isolates from 2 free-standing pediatric centers were obtained from respiratory samples from patients with cystic fibrosis during 2015-2017. Stored isolates were cultured on blood agar (Thermo Fisher Scientific) at 35±1°C for 18-24 hours. A 0.5 McFarland suspension was prepared with Sensititre® demineralized water. Final inocula of 5 × 10E 5 CFU/mL were prepared in Sensititre® Mueller-Hinton broth. Custom-prepared Sensititre® MIC plates (Thermo Fisher Scientific) containing C/T and 10 comparator antimicrobials were inoculated and incubated at 35±1°C for 18-24 hours. MICs were determined via Sensititre Vizion® system. MIC endpoints (susceptibilities) were interpreted by CLSI (2018) breakpoint criteria.
Results. Data from 83 unique isolates from 2 sites (Missouri: 38 and Texas: 45) for the years 2015-2017 are reported. Overall, 90% of the tested isolates were C/T susceptible (MIC ≤4 μg/mL), while susceptibility for colistin, meropenem, and ciprofloxacin were 93%, 88%, and 86%, respectively (Table 1) . C/T exhibited high overall activity (MIC50/90, 1/4 μg/mL) against these Pseudomonas isolates. C/T was more active than amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, gentamycin, meropenem, piperacillin-tazobactam and tobramycin against tested Pseudomonas isolates but less active than colistin.
Conclusion. C/T had broad-spectrum activity and high potency against most Pseudomonas aeruginosa from 2 geographically diverse pediatric US medical centers.
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Delafloxacin Activity Against

Background.
Delafloxacin is a recently approved anionic fluoroquinolone antibiotic with broad-spectrum activity against Gram-positive and Gram-negative organisms. The drug has been approved for patients with acute bacterial skin and skin structure infections including those caused by methicillin-resistant S. aureus. There is limited data available against methicillin-resistant S. aureus blood isolates (MRSABI), vancomycin intermediate strains (VISA), vancomycin-resistant strains (VRSA), daptomycin non-susceptible strains (DNSSA) and linezolid-resistant S. aureus (LRSA).
Methods.
Antimicrobial activity of delafloxacin, levofloxacin, vancomycin, daptomycin, ceftaroline, and linezolid was determined against recent (2016-2018) MRSABI (110), VRSA (15), VISA (35), DNSSA (40), and LRSA (6). Broth microdilution testing using Mueller-Hinton broth was used to determine minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) according to CLSI guidelines. FDA breakpoints were used to determine delafloxacin susceptibility, and CLSI breakpoints were used for all other antibiotics.
Results None of the LRSA were susceptible to delafloxacin or levofloxacin. All strains that were susceptible to the antimicrobial agents above had an MBC that was the same as the MIC or one dilution greater except for linezolid which demonstrated an MBC that was more than eight-fold greater than the MIC. For MRSABI isolates with a levofloxacin MIC ≥ 8 mg/L (55/110) suggesting multiple mutations in the quinolone-resistant determining region, the delafloxacin MIC 90 was 1 mg/L with a 36.4% susceptibility rate.
Conclusion. Delafloxacin demonstrates superior activity to levofloxacin against recent MRSA blood isolates, VISA, VRSA, and DNSSA.
